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THE ROLE OF PERCUTANEOUS TRANSJUGULAR
PORTOSYSTEMIC SHUNTS
ABSTRACT
Zemel, G., Katzen, B.T., Becker, G.J., Benenati, J.F. and Sallee, D.S. (1991)
Percutaneous trans]ugular portosystemic shunt. Journal of American Medical
Association 266: 390-393.
Objective. To determine the effectiveness of the Palmaz balloon expandable stent
for the creation of a transjugular intrahepatic portosystemic shunt. The device is
designed to achieve portal decompression in patients with variceal hemorrhage
secondary to portal hypertension.
Design. Transjugular intrahepatic portosystemic shunting was performed in
eight patients during a 9-month period. Mean follow-up was 5 months.
Patients. All patients had cirrhosis with portal hypertension and varices.
Bleeding occurred in seven patients from esophageal varices and in one patient from
hemorrhoids.
Main Outcome Measures. Shunt patency and recurrent variceal hemorrhage.
Results. Shunts created from a transjugular approach between a hepatic and a
portal vein (diameters of 8 to 12 mm) lowered the average portosystemic pressure
gradient from 36 to 11 mm Hg. Mean postoperative hospital stay was 7.7 days.
Complete variceal decompression after transjugular intrahepatic portosystemic
shunt placement was identified endoscopically in all eight patients. The patient
treated for hemorrhoids rebled and was treated successfully by transfemoral balloon
expansion of the shunt diameter from 8 to 12 mm. All shunts were patent at 1 to 9
months (mean, 5 months) of follow-up.
Conclusion. Initial results suggest that transjugular intrahepatic portosystemic
shunt is a safe and effective method of portal decompression for the treatment of
variceal hemorrhage.
PAPER DISCUSSION
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The creation of a transjugular intrahepatic portosystemic shunt (TIPS) in experi-
mental animals was first described by Rosch, Hanafee and Snow in 19691. Although
they could establish these shunts, they could not solve the problem of keeping the
shunt patent. In 1982, Colapinto et al. described using the technique in humans
utilizing balloon dilatation of the intrahepatic tract, but they too were unsuccessful288 HPB INTERNATIONAL
in achieving durable patency of the shunt2. The introduction of the metallic
intravascular stent provided the technological advance needed to maintain patency
of the intrahepatic shunt, described in animals by Palmaz et al. in 19853 and in
humans by Richter et al. in 19904.
Using a metallic stent, TIPS offers the promise of providing a simple, effective
non-operative method for treating portal hypertension by means of intrahepatic
portosystemic shunting. The first patients were treated by Richter in Germany
using the Palmaz stent4. Excellent results were achieved but the early technique
was complex and lengthy, involving both a transjugular and a transhepatic
approach. This group now has treated over 50 patients.
The paper by Zemel et al. from Miami is the first published series in the USA
using the Palmaz stent. The excellent results achieved in their first eight patients
corroborate the results achieved by Richter’s group using the Palmaz stent.
Other vascular stents are available and at UCSF we have employed" the more
flexible Wallstent in over 50 patients5. The Wallstent is somewhat easier to
employ and is perhaps more versatile than the Palmaz stent. The key question,
however, will concern long-term patency of the shunt and whether one stent type is
better than another in this respect.
Zemel et al. reported a 100% assisted primary patency rate. This involved second
procedures in one patient 19 days after initial shunting and in two patients 4 months
after initial shunting. The first patient rebled, but the authors were able to
successfully dilate the original stent from a diameter of 8 mm to 12 mm. This
reduced the pressure gradient and bleeding ceased. Since blood flow is proportional
to the fourth power of the radius of the stent a diameter increase from 8 to 12 mm
will produce an increase of about 500% in bloodflow through the shunt.
Narrowings in the hepatic vein segment of the shunts of the other two patients were
also successfully treated by percutaneous transvenous balloon dilatation.
It therefore appears that not only can TIPS be placed simply and safely by
percutaneous techniques but, in addition, the shunt can be enlarged or modified at
a later stage by equally simple percutaneous techniques. Further developments
may perhaps even allow the shunt to be narrowed at a later stage if encephalopathy
is a problem. A better understanding of the cause of post-shunting liver failure and
encephalopathy may emerge if variable partial shunting becomes practical.
At this preliminary stage of clinical investigation the optimal shunt diameter has
not yet been established. Should shunt diameter be selected on the basis of
achieving a target pressure gradient across the shunt; should it be based on
angiographic studies showing no flow to varices; should the aim be to maintain flow
to the liver; or should a smaller shunt diameter be chosen initially to minimize
potential encephalopathy reserving the option of subsequent stent dilatation to
increase shunting if bleeding recurs? Current techniques employ standard vascular
stents that are dilatated up to the required diameter of 8-, 10- or 12 mm using the
appropriate sized balloon catheter. These sizes were used because these were the
currently available sizes that were in use in the arterial tree and the biliary tract.
It may become clear that larger stents have to be developed or that stents placed
in parallel using two hepatic veins produce better results. Work by Rypins and
Sarfeh and by Johansen suggest that small diameter surgical shunts in the 8 to 12
mm range are effective at decompressing portal hypertension and have low rates of
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The indications for shunting in Zemel’s study were variceal bleeding as a result of
portal hypertension in seven of eight patients and hemorrhoidal bleeding in one
patient. The severity of cirrhosis was classified as 2 Childs A, 5 Childs B, and 1
Childs A. In our initial 42 patients treated at UCSF the patients had much more
severe cirrhosis, with 2 Childs A, 8 Childs B, and 34 Childs C. Two patients were
successfully treated for intractable ascites, but the remainder all had recurrent
variceal bleeding after sclerotherapy. Sixteen patients were actively bleeding at the
time of shunting and 24 had suffered recurrent bleeds (average 3.6 episodes) within
the previous few days. Fifteen of our 16 actively bleeding patients ceased bleeding
at the time of shunt placement. The sixteenth patient continued to bleed and
endoscopy revealed a bleeding duodenal ulcer. The shunt was patent and there was
no variceal bleeding. This experience suggests that TIPS may be a good treatment
for both acute and recurrent variceal bleeding and we are embarking on a
prospective randomized clinical trial comparing TIPS and sclerotherapy.
Zemel et al. mention an additional role for TIPS in the treatment of patients with
end-stage liver disease who are candidates for liver transplantation. The first 13
patients whom we treated at UCSF were in this category8. In all these patients TIPS
provided acute control of variceal bleeding eliminating the need for emergency
transplantation. Time was thus available to find suitable liver donors and the
surgery of transplantation was not complicated by prior shunt surgery. Seven of
these patients successfully underwent subsequent liver transplantation. The avail-
ability of the excised livers was a great windfall allowing histopathologic study of
the shunt at various stages of maturity ranging from four days to three months9. It
appears that by three weeks the luminal surface of the stent had become covered by
a thin layer of granulation tissue with a single layer of endothelial cells. In a sense,
an artificial blood vessel had been created within the liver parenchyma with the
metallic stent as a scafold.
As shown by Zemel et al. the transjugular route appears safe and the shunts
effective. The next few years promise great advances in this field not only in the
treatment of portal hypertension and bleeding, but also in the histopathologic study
of intrahepatic stents in transplant patients. Direct access to the portal system
provides the potential for significant physiological studies in many fields of portal
dynamics and liver function.
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